Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 1785-1791, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yandle, T.
Right arrow Articles by Espiner, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yandle, T.
Right arrow Articles by Espiner, E.

Clinical Chemistry, Vol 38, 1785-1791, Copyright © 1992 by American Association for Clinical Chemistry

Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors

T Yandle, M Richards, M Smith, C Charles, J Livesey and E Espiner
Department of Endocrinology, Princess Margaret Hospital, Christchurch, New Zealand.

We developed a fluorometric assay for endopeptidase-24.11 (EC 3.4.24.11) in human plasma. Substrate [glutaryl-Ala-Ala-Phe- amidomethylcoumarin(AMC)] was incubated with plasma (20 microL, 30 min, pH 7.6) with (control) or without the endopeptidase-24.11 inhibitor phosphoramidon. Further incubation with aminopeptidase M released free AMC. Within-assay CVs were 4.5% and 8.6%, respectively, at 3.31 and 0.27 nmol of AMC released per milliliter per minute. The between-assay CV was 10.4% at 0.31 nmol/mL per minute and the detection limit was 0.05 nmol/mL per minute. A highly skewed distribution of endopeptidase- 24.11 in 41 normal samples was found, ranging from 0.12 to 6.84 nmol/mL per minute (median = 0.44). Mean endopeptidase-24.11 concentrations were significantly higher in hypertensive subjects (0.68 nmol/mL per minute) than in normotensive subjects (0.34 nmol/mL per minute; P less than 0.05). Compared with placebo administration, the oral endopeptidase-24.11 inhibitor UK 79300 significantly inhibited the plasma enzyme at doses of 100 mg (twice daily). Although in normotensive subjects the enzyme was unaffected with doses of 25 mg, the same dose (25 mg) inhibited the plasma enzyme in hypertensive subjects. No activity was detected in sheep plasma, but addition of exogenous endopeptidase-24.11 to sheep plasma in vitro allowed in vivo assessment of the effect of infused endopeptidase-24.11 inhibitor SCH 39370.


The following articles in journals at HighWire Press have cited this article:


Home page
 HypertensionHome page
G. I. Rice, A. L. Jones, P. J. Grant, A. M. Carter, A. J. Turner, and N. M. Hooper
Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study
Hypertension, November 1, 2006; 48(5): 914 - 920.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton
Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure
Circulation, February 21, 2006; 113(7): 977 - 985.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Trebbien, L. Klarskov, M. Olesen, J. J. Holst, R. D. Carr, and C. F. Deacon
Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E431 - E438.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
Pacific Study Group and B. Neal
Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 270 - 276.
[Abstract] [PDF]

Home page
 J. Appl. Physiol.Home page
J. B. Morris, J. Stanek, and G. Gianutsos
Sensory nerve-mediated immediate nasal responses to inspired acrolein
J Appl Physiol, November 1, 1999; 87(5): 1877 - 1886.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. J. Campbell, A. Kladis, T. A. Briscoe, and J. Zhuo
Type 2 Bradykinin-Receptor Antagonism Does Not Modify Kinin or Angiotensin Peptide Levels
Hypertension, May 1, 1999; 33(5): 1233 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. J. Campbell, F. Anastasopoulos, A.-M. Duncan, G. M. James, A. Kladis, and T. A. Briscoe
Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats
J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 567 - 577.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Anastasopoulos, R. Leung, A. Kladis, G. M. James, T. A. Briscoe, T. P. Gorski, and D. J. Campbell
Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes
J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 799 - 805.
[Abstract] [Full Text]

Home page
 HypertensionHome page
C. J. Charles, E. A. Espiner, A. M. Richards, and E. J. Sybertz
Endopeptidase Inhibition in Angiotensin-Induced Hypertension : Effect of SCH 39370 in Sheep
Hypertension, July 1, 1995; 26(1): 89 - 94.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.